Objectives: The study aims were to characterize women with fecal incontinence (FI) and measure changes in FI severity and quality of life 3 and 12 months after treatment.
T he International Consultation on Incontinence defines fecal incontinence (FI) as the involuntary loss of solid or liquid stool that is a social or hygienic problem, whereas consistency of stool and frequency of occurrence are also important components of defining FI. 1, 2 Fecal incontinence is relatively common, with a prevalence of 11% to 15% among community-dwelling adults. 3Y6 The prevalence of FI may indeed be underestimated with up to 50% of patients often not discussing the problem with their physicians. 4 Fecal incontinence affects individuals of all ages but is more common in older women. 5 Other risk factors include diarrhea, the presence of multiple chronic illnesses, and coexisting urinary incontinence. 6 Various modalities are available for the treatment of FI. These include behavioral modifications, dietary changes, medications, anal sphincter muscle exercises with biofeedback, injectable agents, and surgical procedures, such as sacral neuromodulation and sphincteroplasty. The Cochrane Collaboration review of surgical treatment of FI noted small numbers of relevant trials, small sample sizes, and methodological weaknesses as limitations to this literature. 7 A recent Cochrane Collaboration review update on biofeedback and sphincter muscle exercises for FI concluded that adding biofeedback to anal sphincter muscle exercises and electrical stimulation was better at reducing FI than either exercises or electrical stimulation alone. 8, 9 Furthermore, little is known of the long-term success of treatments for FI and their effect on quality of life (QoL).
This study was conducted by the Pelvic Floor Disorders Network as a secondary analysis of a larger study examining adaptive behaviors among women with bowel incontinence (ABBI). Using a series of validated questionnaires, this study aimed to characterize a cohort of women with FI and prospectively measure improvements in symptoms and condition-specific QoL 3 and 12 months after clinically selected, nonstandardized treatments (usual care). As an exploratory analysis, we also compared prospectively measured FI symptoms and impact on conditionspecific QoL at 3 and 12 months between women who had surgery and those with nonsurgical treatments.
The ABBI study was conducted through the Pelvic Floor Disorders Network, a clinical trials network that currently consists of 8 clinical sites and a data coordinating center. As part of a larger study evaluating adaptive behaviors among women with pelvic floor disorders, an Adaptation Index has been developed and validated using the data from this cohort study. 10 To develop and validate the Adaptation Index, women with FI were recruited from referral-based specialty care clinics. Women met the eligibility criteria if they had a primary complaint of FI consisting of liquid stool, solid stool, or mucous occurring at least monthly for 3 consecutive months and were planning treatment of FI. We excluded women with prior rectal or colon cancer, inflammatory bowel disease, pelvic irradiation, a current or prior rectal fistula(e), removal of any portion of the colon/rectum, rectal prolapse, or severe neurological conditions. Each clinical site and the data coordinating center received institutional review board approval, and all subjects provided written informed consent.
Women received nonsurgical and surgical treatments for FI per usual care. Nonsurgical treatments included behavioral therapy, pelvic floor muscle exercises with and without instrumented biofeedback, medications (including supplementary fiber), or a combination of these treatments. Surgical treatment of FI could be combined with other pelvic floor surgeries and/or nonsurgical interventions. Surgical intervention included anal sphincter repair but did not include sacral neuromodulation for FI because the study occurred before the FDA approval of neuromodulation for FI.
Measures
Subjects completed validated questionnaires by either telephone (by a central interviewing center) or in person before treatment, 3 months after treatment per usual care, and again at 12 months after treatment. Validated questionnaires assessed bowel symptoms, impact on health-related QoL and general QoL, and other pelvic floor symptoms. Questionnaires included the Fecal Incontinence Severity Index (FISI) 11 and the Modified Manchester Health Questionnaire (MMHQ). 12 The FISI has 4 questions on incontinence of gas, mucus, liquid stool, and solid stool. 11 The frequency of incontinence symptoms ranged from 2 or more times a day, once a day, 2 or more times a week, once a week, 1 to 3 times per month, or never. Responses are weighted on a severity scale with scores from 1 to 20, and the total FISI score is calculated (range, 0Y61). The patientweighted scores were used in this analysis with a higher score indicating a greater impact or greater severity of symptoms. Fecal Incontinence Severity Index scores of 0 indicated continence. The MMHQ is a validated questionnaire that reflects the overall impact of FI on QoL and consists of a total score and 8 domain scores (31 questions). 12 Specific items are measured on a 5-point scale as 1 (''never'') to 5 (''always''). Total scores and domain scores both range from 0 to 100. The FISI is incorporated in the American English version of the MMHQ. 12 The minimal important clinical difference values based on anchorbased methodology for the FISI are j4 and j3, respectively, from this same study. 13 Additional pelvic floor disorder symptoms were assessed with 2 separate composite questionnairesVThe Pelvic Floor Distress Inventory and the Pelvic Floor Impact Questionnaire. 14 Each questionnaire has 3 scales (urinary, colorectal, and pelvic organ prolapse) with the individual scales having psychometric data for validity, reliability, and responsiveness to change. 15 The 46-item Pelvic Floor Distress Inventory assesses symptom distress in women with pelvic floor disorders and has 3 scales as follows: the Urinary Distress Inventory (range, 0Y300), the Pelvic Organ Prolapse Distress Inventory (range, 0Y300), and the Colorectal-Anal Distress Inventory (CRADI; range, 0Y400). 14 Similarly, the Pelvic Floor Impact Questionnaire measuring the impact of bladder, bowel, and vaginal symptoms on a woman's daily activities, relationships, and emotions is composed of 3 scales of 31 questions each; these are as follows: the Urinary Impact Questionnaire (range, 0Y400), the Pelvic Organ Prolapse Impact Questionnaire (range, 0Y400), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range, 0Y400). 14 In all measures, a higher score indicates worse symptom bother or greater impact of symptoms on daily functioning. The minimal important difference (MID) values based on anchor-based methodology were j11 for the CRADI and j18 for the CRAIQ. 15 Participants completed the Medical Outcomes Study Short Form (SF-12), a shortened validated version of the SF-36, to measure the impact on general QoL. 16 The SF-12 has 2 scales, the mental and physical component summary scales (range, 0-100), where a higher score indicates better health-related QoL. The Patient Global Impression of Improvement Scale is a selfrated assessment of change after treatment and has 7 response levels ranging from ''very much worse,'' ''no change,'' to ''very much better.'' 17 For this analysis, we dichotomized the data to compare those who were better (better, much better, and very much better) to those who were not improved (no change, worse, much worse, and very much worse).
Subject Characteristics
Demographic and medical history variables were collected at baseline including age, race, education, type of medical insurance, and smoking status. Body mass index was obtained from self-reported values and recorded in kilograms per square meter. Self-reported medical history included parity, diabetes, connective tissue disease, and prior FI treatments, including prior physical therapy, biofeedback, and surgery. The Bristol Stool Form Scale was assessed at baseline to characterize the most common type of stool consistency. 18 Rome III Clinical Criteria were used to define irritable bowel syndrome (IBS). 19 
Analysis
The analytic sample included women who received treatment per usual care (within 6 T 2 weeks after consent) and had at least 1 of the 4 questionnaires complete at 3 months and 12 months. Demographic and medical history variables were compared among women who were included in the analytic sample versus those who dropped out, withdrew, or did not receive treatment for various reasons. We evaluated the change of questionnaire scores from baseline at 3 and 12 months after treatment using 1-sample paired t test for the overall study cohort. We also evaluated differences within surgical treatment group and the nonsurgical treatment group using 1-sample t test. A between group comparison was also performed at 3 and 12 months to explore any group differences using the Wilcoxon 2-sample test. P values of 0.05 or less were considered statistically significant. Analyses were performed in SAS 9.2 for Windows (SAS Inc, Cary, NC). Figure 1 displays the flow of study subjects. Among the 133 women who were recruited in the study, 43 were considered lost to follow-up at 3 months. More than one third (15/43, 35%) of the women lost to follow-up did not receive treatment within 6 T 2 weeks. An additional 13 women were lost to follow-up at 12 months. Among the 90 women who were observed at 3 months, 7 women did not complete any of the questionnaires, whereas among the 77 women who were observed at 12 months, 6 women did not complete any of the questionnaires.
RESULTS
There were no significant differences for any demographic variables, medical history, or previous treatments for FI (all P 9 0.05, data not shown) comparing women who received treatment per usual care approaches and completed at least 1 of the questionnaires at 3 months (n = 83) to those that did not (n = 50). Women who completed at least 1 of the 12-month questionnaires (n = 71) were slightly older (60 T 13 years vs 55 T 15 years, P = 0.05) than women who did not receive treatment or did not complete questionnaires (n = 62).
Participants' demographics, medical history, and prior treatment of FI are outlined in Table 1 . The study cohort had an average age of 57.4 T 14.1 years, a median parity of 2 (range, 0Y9), an average BMI of 28.9 T 6.8 kg/m 2 , and 11.3% were African American. Thirty-one percent of the women had a clinical diagnosis of IBS, with more women having diarrhea predominant IBS or mixed (constipation and diarrhea) predominant IBS. Stool consistency types varied, with the most common stool consistency reported as a Bristol Stool Form Scale, type 4 (stool like a sausage or snake, smooth and soft).
Clinically determined and applied FI treatments are shown in Table 2 . Although most women received more than 1 treatment type, the most common treatments recorded at 3 months were fiber supplementation (41%) and pelvic floor muscle exercises (43%). Twenty women (22%) received surgical treatment of FI.
Fecal incontinence severity and impact on QoL significantly improved and met criteria for MID after treatment (P G 0.001; Table 3 ). Other colorectal symptoms and the impact of these symptoms on QoL also significantly improved after FI treatment (P G 0.001). The impact of FI on general mental health improved 3 months after FI treatment (P = 0.001), although no significant change was noted for improvements in general physical health (P = 0.80). No significant worsening or improvements in questionnaire scores were noted between 3 months and 12 months after FI treatment, with the exception of the improvement of general physical health scores (P = 0.03). All questionnaire scores at 12 months compared with baseline scores were significantly improved (P G 0.05), except for the SF-12 general physical health component summary score (P = 0.07).
As an exploratory analysis, changes in outcome measure scores were compared in women who received surgical Table 4 . Overall, the 20 women who had surgical FI treatment and the 63 women who received nonsurgical treatments had significant improvements in questionnaire scores at 3 months and 12 months after treatment compared with baseline scores. Women who had surgical treatments had greater improvements in FI severity (FISI scores), colorectal symptoms (CRADI scores), and impact on QoL (CRAIQ and MMHQ scores) at 3 months than women receiving nonsurgical treatments (P G 0.05, data not shown). The improvements in scores among women receiving surgical FI treatments persisted at 12 months (P G 0.05), with the exception of FI severity (P = 0.32, data not shown). Both groups had improvements in the FISI, CRADI, CRAIQ, and MMHQ scores that met thresholds of MIDs. Within the overall cohort, 14% (12/83) of the women had complete resolution of FI at 3 months, and only 7% (5/71) of these women remained continent at 12 months. 
DISCUSSION
This study has demonstrated that FI severity, colorectal symptoms, and condition-specific QoL significantly improves within the first 3 months after usual care treatments and is maintained up to 12 months. This study adds important information to the few studies investigating long-term efficacy and durability of nonsurgical and surgical FI treatments. The data presented in this study could also contribute to estimates of effect size for future clinical trials involving treatment of FI.
In 2003, Norton et al 20 reported a randomized trial comparing 171 patients with FI who were randomized to 1 of 4 groups; these are as follows: (1) standard care (advice); (2) advice plus instruction on sphincter exercises; (3) hospital-based computerassisted sphincter pressure biofeedback; and (4) hospital biofeedback plus the use of a home electromyelogram biofeedback device. Biofeedback was no different than standard care with advice (53% improved in group 3 vs 54% in group 1), and there were no differences among the groups on episodes of incontinence, continence score, or QoL. Although there were no differences among groups, efficacy was maintained at 1 year for all subjects. In another randomized controlled trial comparing biofeedback to pelvic floor muscle exercises, FI severity improved in the biofeedback group (FISI scores 33 at baseline improved to 23 at 3 months) compared with that in the group receiving pelvic floor muscle exercise advice (FISI scores 35 at baseline to 32 at 3 months). 21 A few additional uncontrolled studies reported similar outcomes with significant improvement in FISI scores (7 points) after multicomponent behavioral therapy along with medications, 63% of patients continent at 1 year in another study using biofeedback, and another reported that most responders are still improved at 5 years after biofeedback therapy for FI. 22Y24 Although this current study is not a randomized controlled trial, this cohort study adds information on clinical changes in symptoms after usual care for FI among 7 specialty referral clinical sites in the United States. In much of medicine, and in studies investigating FI in particular, the ''best current therapy'' has not yet been identified and many ''standard'' practices have not been validated in clinical trials. Moreover, no studies have been identified to explore how to select patients for conservative or surgical treatment; therefore, patient selection remains empirical. 1 The most recent consensus from the International Consultation on Incontinence, Fourth Edition stated that, ''expert consensus in this committee and the world literature is unanimous in recommending conservative interventions, singly or in combination, for the majority of patients with FI as first-line treatment.'' 1 Without good pathophysiologic or clinical evidence for superiority of 1 practice over another, usual care studies, such as this one, allow us to encompass a wide variety of practice styles that are difficult to explain. 25 This type of study may also be considered preliminary to trials of experimental conservative therapies, new drugs or devices, or for treatment strategies that are not part of usual care practices. In pragmatic effectiveness trials, where the research question per se is to determine if a treatment approach is superior to usual care, should obviously have de facto usual care as the control group, and this study provides some preliminary guidance to future studies in this area.
Although this analysis was not powered to detect statistically significant changes between the 2 subgroups nor was this study a randomized trial, differences were noted in an exploratory analysis between the surgical and nonsurgical treatment groups. First, women who had surgery had greater improvements in FI severity at 3 months than the nonsurgical group. However, improvements in FI severity were not different at 12 months in either group. Second, women receiving surgical anal sphincter repair had a larger magnitude of improvement in the condition-specific QoL scores at 3 and at 12 months in comparison to women receiving nonsurgical treatments. Continence rates were not compared between the 2 groups given the small numbers of women who achieved continence (n = 12) at 3 and 12 months. Women with sphincter tears undergoing anal sphincter surgery may have also had baseline differences in other characteristics, such as complicated deliveries, that were not collected for this analysis. Ultrasound evidence of anal sphincter tears was not collected. Furthermore, it is not known what type of preoperative and perioperative education was given regarding diet and pelvic floor muscles exercises for the women having surgical FI treatment. More data are needed on the 5-year durability after surgical and nonsurgical treatments for FI.
Regardless of the type of treatment received, both groups improved in FI severity and condition-specific QoL at 3 and 12 months after treatment. Overall, women in the surgical and nonsurgical groups met the thresholds for achieving MID in the FISI (MID, j4 points), MMHQ (MID, j3 points), CRADI (MID, j11 points), and CRAIQ (MID, j18 points). 13 Based on a conservative method of estimating the MID as the change from baseline to 3 months in scale scores that correspond to an effect size of 0.5 (SD, 1/2), all condition-specific measures in this study demonstrate clinically meaningful changes to patients, which are maintained at 12 months. 13 ,26Y29 More data regarding patient-reported outcome measures and validated tools to measure a clinically meaningful change in scores after treatment are needed for FI intervention studies.
The strengths of this study are its multicenter, prospective design that includes multiple providers of usual care treatments for FI and the assessment of outcomes using validated and reliable questionnaires over a 1-year period. In addition, these data allow for comparison of different types of treatment and their durability over a 12-month period. The main limitations are also inherent in the usual care, prospective cohort design. Participation bias could be present as subjects were asked to participate in the study. A selection bias may exist among the types of treatments chosen by the participants and providers. Migration of usual care over time has important implications in future trial design because there is no way to guarantee that usual care during this study will reflect usual care during conduct of future trials. Other limitations are as follows: individual treatment components cannot be individually studied (dietary advice, medications, exercises instruction given together, type of surgery performed), women who initially received surgical care may have had concomitant nonsurgical treatments, the lack of documented data on sphincter muscle injuries by ultrasound, and there was a significant dropout rate after consent was obtained. This may reflect the usual care treatment strategies of the study and recruitment from referral-based practices or lack of treatment efficacy. Although we were unable to detect important differences between subjects who did and did not follow up, this should raise awareness in the recruitment and retention for trials investigating FI in the future.
CONCLUSIONS
Women seeking treatment of FI have significant and clinically meaningful improvements in FI severity and QoL during the first year after both surgical and nonsurgical treatments. The largest gain after FI treatments occurs during the first 3 months and persists to 12 months. Data provided on the clinically meaningful change in questionnaire scores after treatment may inform future FI intervention studies on relevant patient-reported outcomes.
